Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
Date:4/20/2012

NEW YORK, April 20, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP).   

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) Chelsea's Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company's numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera's clinical trials, were materially false and misleading.

Request more information now by clicking here:  www.faruqilaw.com/CHTP

Take Action
If you purchased Chelsea securities between November 3, 2008 and March 28, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/CHTP.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Chelsea's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
2. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
4. Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler
5. Frost & Sullivan: Industry Push toward Quantitative Imaging Positions Computer Aided Detection and Diagnosis Adequately for Renewed Clinical Expansion
6. Frost & Sullivan: U.S. Nuclear Medicine and PET Imaging Systems Market Witnessed a Rebound in 2010, With PET Blazing the Trail
7. Frost & Sullivan Recognizes Sensear for Innovative and Effective Product Differentiation in the PPE Market
8. Talysts CEO is Nominated for the Ernst & Young Entrepreneur of the Year Award
9. R&D Trends: Depression - Clinical attrition driven by mature market conditions
10. Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai
11. PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... SILVER SPRING, Md. , March 28, 2017 ... today approved Dupixent (dupilumab) injection to treat adults ... for patients whose eczema is not controlled adequately ... therapies are not advisable. Dupixent can be used ... approval of Dupixent demonstrates our commitment to approving ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer ... on the various indicators and trend analysis related ... drugs in mainstream pharmaceutical market in US. The ... for the growth on cancer generics drugs in ... in saving of billions of dollars for various ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
Breaking Medicine Technology:
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot ... team of professional staff discussed strategies for preventing outbreaks among camp communities during ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all ... February 8-10. , This event was exclusive to providers and offered an opportunity ... meeting took place at the Manchester Grand Hyatt where attendees gathered for a lively ...
Breaking Medicine News(10 mins):